Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH
Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH Professional audiences…
Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for pertussis vax
Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for…
Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis
Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis Professional…
Lucid Diligence Brief: Iambic Takeda AI drug discovery collaboration
Lucid Diligence Brief: Iambic Takeda AI drug discovery collaboration…
Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance
Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance…
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause Professional…
Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D
Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D…
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization Professional…
Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to MeiraGTx
Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to…
Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA
Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA…
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen
Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen…
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission Professional audiences…